# NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX as Conversion Therapy of Locally Advanced Pancreatic Cancer

> **NCT06669078** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 120 (estimated)

## Conditions studied

- Locally Advanced Pancreatic Cancer

## Interventions

- **DRUG:** Nal-lRl+Oxaliplain+5- FU +PD 1
- **DRUG:** Nal-lRl+Oxaliplain+5- FU

## Key facts

- **NCT ID:** NCT06669078
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10-30
- **Primary completion:** 2027-10-15
- **Final completion:** 2027-10-15
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06669078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06669078, "NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX as Conversion Therapy of Locally Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06669078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*